Advisor Group’s Seres Therapeutics MCRB Stock Holding History

Advisor Group’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$33K	Hold	480	–	–	﹤0.01%	3679
2019 Q3	$38K	Buy	480 +15	+3%	+$991	﹤0.01%	3577
2019 Q2	$30K	Hold	465	–	–	﹤0.01%	3699
2019 Q1	$64K	Sell	465 -14	-3%	-$1.71K	﹤0.01%	3207
2018 Q4	$43K	Buy	479 +4	+0.8%	+$560	﹤0.01%	3289
2018 Q3	$72K	Buy	475 +50	+12%	+$8.09K	﹤0.01%	3002
2018 Q2	$73K	Buy	425 +70	+20%	+$11.4K	﹤0.01%	2786
2018 Q1	$52K	Sell	355 -19	-5%	-$3.64K	﹤0.01%	3031
2017 Q4	$76K	Sell	374 -11	-3%	-$2.26K	﹤0.01%	2785
2017 Q3	$124K	Sell	385 -318	-45%	-$86.9K	﹤0.01%	2234
2017 Q2	$160K	Buy	703 +353	+101%	+$72.5K	﹤0.01%	1947
2017 Q1	$79K	Buy	+350	New	+$71K	﹤0.01%	2343

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisor Group's MCRB Position: Q4 2019 in Review

Advisor Group held its Seres Therapeutics (MCRB) position steady in Q4 2019 at 480 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #3679.

Advisor Group first reported a position in MCRB in Q1 2017 and has held it in 12 quarters since. The position peaked at $160K in Q2 2017. 79 funds tracked by Wall St. Rank hold MCRB as of Q4 2019.

Advisor Group held 480 shares of Seres Therapeutics worth $33K as of Q4 2019.
Advisor Group left its Seres Therapeutics share count unchanged in Q4 2019.
Seres Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3679 holding.
Advisor Group first reported a position in Seres Therapeutics in Q1 2017 and has held it in 12 quarters since.
Advisor Group's Seres Therapeutics position peaked at $160K in Q2 2017.
79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.